Skip to main content
UC Davis School of Medicine

UC Davis School of Medicine

NEWS | March 7, 2017

UC Davis joins national consortium to find regenerative treatments for dental and craniofacial tissues

(SACRAMENTO, Calif.)

UC Davis will join other California research institutions in a three-year, $12 million effort to find regenerative treatments for dental, oral and craniofacial deformities and injuries.

Nancy Lane Nancy Lane

Nancy Lane, an endowed professor of medicine, rheumatology and aging research and director for the UC Davis Center for Musculoskeletal Health, will serve as principal investigator for the UC Davis team.

"We are excited to work with investigative teams to develop treatments for craniofacial problems,” she said. “Our investigations in how to direct mesenchymal stem cells to stimulate new bone formation will complement the expertise of our research partners and can help speed the discovery of more effective approaches to the conditions facing patients.” 

UC Davis is part of the California-based Center for Dental, Oral & Craniofacial Tissue & Organ Regeneration (C-DOCTOR), which includes UC San Francisco, UC Berkeley, UCLA, University of Southern California, Stanford University, as well as industry partners. C-DOCTOR will serve as one of two national resource centers comprising the Dental, Oral, and Craniofacial Tissue Regeneration Consortium of the National Institute of Dental & Craniofacial Research (NIDCR).

The UC Davis Center for Musculoskeletal Health is the administrative center for this award. Other  resource service groups at UC Davis that may be involved include the New Technology and Unifying Research (CENTAUR), Institute for Regenerative Cures, Good Manufacturing Practice facility, Department of Biomedical Engineering and the Department of Orthopaedic Surgery. 

C-DOCTOR will be a national resource for the recruitment, cultivation and clinical translation of innovative regenerative technologies to replace dental and craniofacial tissues and organs lost to congenital disorders, trauma and disease. Its primary mission is to provide comprehensive clinical, scientific, technical, regulatory, financial and managerial resources to promote cost-effective and timely progression of tissue engineering/regenerative medicine products to human clinical trials. 

“C-DOCTOR is a novel public/private partnership that leverages comprehensive basic/clinical science and innovation programs at the partner institutions with the practical goal of accelerating valuable new therapies to patient benefit,” said Jeffrey Lotz, professor and vice chair of research and an endowed chair of orthopedic surgery at UCSF, which is leading the multi-institution project. “Our working teams include clinicians, scientists, industry experts, patient advocates and other stakeholders, such that C-DOCTOR is optimally organized to identify and refine technologies for clinical adoption in ways not previously possible.” 

C-DOCTOR is actively recruiting additional industry partners (contact: Dr. Jeffrey Lotz, jeffrey.lotz@ucsf.edu); identifying unmet clinical needs (contact Dr. Yang Chai, ychai@usc.edu); and evaluating mature tissue regeneration technologies (contact Dr. Dezba Coughlin, the Northern California contact, dezba.coughlin@ucsf.edu or Bridget Samuels, the Southern California contact, bdsamuel@usc.edu). 

For more information about C-DOCTOR visit http://c-doctor.org/.